Bladder cancer trials in South Korea

In South Korea 34 Also abroad 626

34 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea
Where
Suwon
Age
18 years and over
People
1
Run by
Janssen Korea, Ltd., Korea
See details and how to joinNCT07735793
Phase 1/2Taking people
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Where
Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
Age
18 years and over
People
340 worldwide
Run by
Inhibrx Biosciences, Inc
See details and how to joinNCT04198766
Phase 1Taking people
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Where
Seoul
Age
18 years and over
People
294 worldwide
Run by
Pfizer
See details and how to joinNCT07206225 · EU 2025-521756-39-00
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Seoul
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Seoul
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Where
Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
Age
18 years and over
People
200 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Jongno -Gu, Seoul
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Chuncheon, Gyeongin, Sangam-dong, Seoul
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Cheongju-si, Ganggu, Seongnam, Seoul
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Gyeonggi-do, Hwasun, Seongnam-si, Seoul
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 3Taking people
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Goyang-si, Hwasun, Seoul, Yangsan
Age
18 years and over
People
454 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00
Phase 3Taking people
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Where
Hwasun, Seoul, Yangsan
Age
18 years and over
People
250 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01
Phase 3Taking people
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Where
Daegu, Seongnam-si, Seoul
Age
18 years and over
People
390 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Daegu, Gyeonggi-do, Seongnam, Seoul
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
No phaseTaking people
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Where
Busan, Daegu, Daejeon, Goyang-si, Incheon, Jeollanam-do, Jeonju, Seoul, Suwon
People
228
Run by
Astellas Pharma Korea, Inc.
See details and how to joinNCT06011954
Phase 1/2Taking people
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Where
Daejeon, Seoul, Suwon
Age
18 years and over
People
317 worldwide
Run by
GI Innovation, Inc.
See details and how to joinNCT04977453
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 1/2Taking people
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Where
Seoul
Age
18 years and over
People
55 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Seoul
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 1Taking people
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Where
Seoul
Age
18 years and over
People
150 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644755
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Daegu, Goyang-si, Incheon, Seoul
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1/2Taking people
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Where
Hwasun, Seongnam, Seoul
Age
18 years and over
People
350 worldwide
Run by
enGene, Inc.
See details and how to joinNCT04752722 · EU 2024-512900-20-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Hwasun, Pusan, Seoul, Suwon
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 3Taking people
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Where
Seoul
Age
18 years and over
People
915 worldwide
Run by
AstraZeneca
See details and how to joinNCT07720284
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Cheongju-si, Goyang-si, Seoul
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00